Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2490
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHeyer, E. E.en
dc.contributor.authorMercer, T. R.en
dc.contributor.authorBarbaric, D.en
dc.contributor.authorMarshall, G. M.en
dc.contributor.authorMacKenzie, K. L.en
dc.contributor.authorTrahair, T.en
dc.contributor.authorGifford, A. J.en
dc.contributor.authorFordham, A.en
dc.contributor.authorMayoh, C.en
dc.contributor.authorFadia, M.en
dc.contributor.authorLukeis, R.en
dc.contributor.authorWood, A. C.en
dc.contributor.authorValvi, S.en
dc.contributor.authorWalker, R. D.en
dc.contributor.authorBlackburn, J.en
dc.date.accessioned2022-11-07T23:32:05Z-
dc.date.available2022-11-07T23:32:05Z-
dc.date.issued2019en
dc.identifier.citation3 , 2019, p. 1-11en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/2490-
dc.description.abstractPURPOSE Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and features associated with relapse. METHODS The cohort comprised eight patients with AP-IMT treated with crizotinib and surgery. Outcome measures were progression-free and overall survival after commencing crizotinib, treatment-related toxicities, features associated with relapse, outcome after relapse, and outcome after ceasing crizotinib. RESULTS The median follow-up after commencing crizotinib was 3 years (range, 0.9 to 5.5 years). The major toxicity was neutropenia. All patients responded to crizotinib. Five were able to discontinue therapy without recurrence (median treatment duration, 1 year; range, 0.2 to 3.0 years); one continues on crizotinib. Two critically ill patients with initial complete response experienced relapse while on therapy. Both harbored RANBP2-ALK fusions and responded to alternative ALK inhibitors; one ultimately died as a result of progressive disease, whereas the other remains alive on treatment. Progression-free and overall survival since commencement of crizotinib is 0.75 6 0.15% and 0.83 6 0.15%, respectively. CONCLUSION We confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with RANBP2-ALK translocated IMT, which suggests that such patients require additional therapy.L20025174742019-08-14 <br />2019-08-16 <br />en
dc.language.isoenen
dc.relation.ispartofJCO Precision Oncologyen
dc.titleCrizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumorsen
dc.typeArticleen
dc.identifier.doi10.1200/PO.18.00297en
dc.subject.keywordsclinical featureen
dc.subject.keywordscohort analysisen
dc.subject.keywordscreatinine blood levelen
dc.subject.keywordscritically ill patienten
dc.subject.keywordsdrug dose reductionen
dc.subject.keywordsfemaleen
dc.subject.keywordsfollow upen
dc.subject.keywordsfractureen
dc.subject.keywordsgamma glutamyl transferase blood levelen
dc.subject.keywordshemoglobin blood levelen
dc.subject.keywordshumanen
dc.subject.keywordsinfanten
dc.subject.keywordsleukocyte counten
dc.subject.keywordslymphen
dc.subject.keywordsmaleen
dc.subject.keywordsmaximum tolerated doseen
dc.subject.keywordsmultiple cycle treatmenten
dc.subject.keywordsneutropeniaen
dc.subject.keywordsneutrophilen
dc.subject.keywordsoutcome assessmenten
dc.subject.keywordsoverall survivalen
dc.subject.keywordsplasma cell granulomaen
dc.subject.keywordsplatelet counten
dc.subject.keywordspotassium blood levelen
dc.subject.keywordspreschool childen
dc.subject.keywordspriority journalen
dc.subject.keywordsprogression free survivalen
dc.subject.keywordspseudotumoren
dc.subject.keywordsretrospective studyen
dc.subject.keywordsschool childen
dc.subject.keywordsside effecten
dc.subject.keywordstreatment durationen
dc.subject.keywordstreatment responseen
dc.subject.keywordsupper respiratory tract infectionen
dc.subject.keywordssodium blood levelen
dc.subject.keywordsalanine aminotransferasealbuminen
dc.subject.keywordsalkaline phosphataseen
dc.subject.keywordsanaplastic lymphoma kinaseen
dc.subject.keywordsaspartate aminotransferaseen
dc.subject.keywordsbilirubinen
dc.subject.keywordscreatinineen
dc.subject.keywordscrizotiniben
dc.subject.keywordsgamma glutamyltransferaseen
dc.subject.keywordshemoglobinen
dc.subject.keywordspotassiumen
dc.subject.keywordssodiumen
dc.subject.keywordsadolescenten
dc.subject.keywordsadolescent diseaseen
dc.subject.keywordsalanine aminotransferase blood levelen
dc.subject.keywordsalbumin blood levelen
dc.subject.keywordsalkaline phosphatase blood levelen
dc.subject.keywordsarticleen
dc.subject.keywordsaspartate aminotransferase blood levelen
dc.subject.keywordsbilirubin blood levelen
dc.subject.keywordscancer controlen
dc.subject.keywordscancer recurrenceen
dc.subject.keywordscancer surgeryen
dc.subject.keywordscancer survivalen
dc.subject.keywordscellulitisen
dc.subject.keywordschilden
dc.subject.keywordschildhood canceren
dc.subject.keywordsclinical articleen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2002517474&from=exporthttp://dx.doi.org/10.1200/PO.18.00297 |en
dc.identifier.risid2311en
dc.description.pages1-11en
item.grantfulltextnone-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

52
checked on Apr 24, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.